Employees: 275
Size Cerus (CERS) is a United States Health Care company (Medical Specialties) with a market value of $392M, the 2850th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.94 on 18 Nov 2026.
Performance Over six months the shares fell 27.9%, against -18.1% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 13.7% over the last twelve months (peer median +14.7%); the operating margin is -12.2% (peer median 6.6%).
Valuation It trades at 1.8× enterprise value to sales against a peer median of 4.1× (8th cheapest of 21).
Capital Return on invested capital runs 35.9 points below its cost of capital (12.9% WACC).
Short interest Short interest is 7.2% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $227M | $206M | $180M | $156M | $162M |
| Revenue growth | — | +14% | +15% | -4% | — |
| Gross profit | $117M | $110M | $97.5M | $84.0M | $84.6M |
| EBITDA | -$25.3M | -$34.3M | -$33.3M | -$54.4M | -$55.8M |
| Net income | -$7.31M | -$15.6M | -$20.9M | -$37.5M | -$42.8M |
| Free cash flow | $328,000 | $1.11M | $8.52M | -$47.8M | -$27.6M |
| Capital expenditure | $3.00M | $3.73M | $2.84M | $4.60M | $2.00M |
| Total debt | $75.0M | $96.9M | $98.1M | $96.0M | $87.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CERS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.0% | -10.9% | 8th lowest of 21 |
| 6-month return | -27.9% | -18.1% | 5th lowest of 20 |
| Distance from 52-week high | -44.1% | -45.3% | 10th highest of 21 |
| Revenue growth (TTM) | +13.7% | +14.7% | 10th lowest of 21 |
| Operating margin | -12.2% | 6.6% | 6th lowest of 21 |
| EV / Sales | 1.8× | 4.1× | 8th cheapest of 21 |
| ROIC minus cost of capital | -35.9 pp | -0.4 pp | 4th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cerus CERS | United States | $392M | -28% | +14% | -12% | 1.8× | n/a | n/a |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 5.5× | -6.3% | +247.0% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | 1.7× | n/a | n/a |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 1.0× | -17.6% | +15.4% |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | 4.6× | 41.7% | +15.9% |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | 1.8× | -9.5% | -6.6% |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | 7.1× | n/a | n/a |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 1.4× | n/a | n/a |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 1.4× | -10.3% | +16.9% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 7.8× | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $406M | -27% | -1% | 19% | 3.9× | 9.6% | +5.6% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | 1.5× | 17.1% | +18.1% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | 218.3× | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 1.8× | -4.2% | -6.0% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 4.8× | 24.9% | +18.8% |
| Jenscare Scientific 9877.HK | Hong Kong | $415M | -32% | +993% | -106% | 17.8× | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $418M | -22% | +46% | 8% | 4.4× | n/a | n/a |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | 24.8× | n/a | n/a |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 1.8× | 19.1% | +0.1% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | 3.7× | -13.1% | +36.8% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 4.2× | 5.7% | +3.4% |